LIB Therapeutics
LIB Therapeutics has appeared in 3 distinct RetailIntel stories in Sep 2026, most often under retail company.
Latest: Sun Pharma signed an exclusive agreement with LIB Therapeutics on September 28 for Lerodalcibep rights outside the United States and China, gaining access to a $3.7 billion PCSK9 market (28 Sep 2026). Earlier, sun Pharma signed a global licensing deal for exclusive rights outside the US and China to commercialise and manufacture Lerodalcibep in the $3.7 billion PCSK9 inhibitor market (28 Sep 2026). Earlier, sun Pharma signed a licensing deal for the $3.7 billion PCSK9-inhibitor market, gaining exclusive rights to manufacture and commercialise Lerodalcibep outside the US and China (28 Sep 2026).
Key figures reported: September 28 (28 Sep 2026); $3.7 billion (28 Sep 2026); 38 per cent (28 Sep 2026); two years to June 2026 (28 Sep 2026).
Brands most often mentioned alongside LIB Therapeutics: Lerochol, Lyrokaul, Sun Pharmaceutical Industries, Sun Pharma.
Most-cited sources on LIB Therapeutics: Business Standard · Companies (2 stories) and ET Small Business (1 story).
- Stories on record: 3
- First seen 28 Sep 2026 · Latest 28 Sep 2026
- Themes: retail company
- Sources cited above: 28 Sep 2026 · 28 Sep 2026 · 28 Sep 2026